Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865650 | 0.82 | CYP2D6 (0.50) | LMNAKMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL3505974 | 0.81 | GAA (0.39) | KMT2APOLBGAAKDM4EL3MBTL1 | |
| SCHEMBL3492650 | 0.81 | GAA (0.54) | LMNAKMT2ACYP2D6CYP2C19POLB | |
| Hydrochloric Acid SCHEMBL8174495 | 0.81 | ITGB3 (0.44) | LMNAKMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL3490964 | 0.79 | KDM4E (0.38) | LMNAKMT2APOLBKDM4EL3MBTL1 | |
| SCHEMBL3489028 | 0.77 | S1PR1 (0.41) | POLBKDM4EL3MBTL1ALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL8175432 | 0.76 | ITGB3 (0.40) | LMNAKMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL21955885 | 0.76 | MEN1 (0.38) | KMT2AGAAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL5271353 | 0.73 | ALDH1A1 (0.36) | KMT2AGAAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL8168279 | 0.73 | MEN1 (0.46) | KMT2AGAAACETDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1855679-B1 | AMINOMETHYL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-1855679-B1 | AMINOMETHYL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2016-06-29 | — | — | EP | disclosed |
| US-8003653-B2 | Imidazolidinone compounds useful as β-secretase inhibitors for the treatment of Alzheimer's disease | Merck. Sharp & Dohme Corp. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7820674-B2 | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820674-B2 | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820674-B2 | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| EP-1409450-B1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARM INC (US) | 2009-12-09 | — | — | EP | disclosed |
| CN-101106994-A | Aminomethyl beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO INC (US) | 2008-01-16 | — | — | CN | disclosed |
| EP-1855679-A2 | AMINOMETHYL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| CN-101068772-A | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARM INC (US) | 2007-11-07 | — | — | CN | disclosed |
| WO-2007058862-A2 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2006078576-A2 | AMINOMETHYL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078576-A2 | AMINOMETHYL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-1409450-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2003006423-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | BACE1, APP, BACE2 | LMNA 500/4885KMT2A 2014/4885CYP2D6 2303/4885 |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | BACE1, APP, BACE2 | LMNA 648/4885KMT2A 1775/4885CYP2D6 1966/4885 |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | BACE1, APP, BACE2 | LMNA 648/4885KMT2A 1775/4885CYP2D6 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.